XWXiaoqi Wang

Xiaoqi Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Xiaoqi Wang has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A Metabolic-Related Gene Signature for Predicting Biochemical Recurrence After Radical Prostatectomy: An Integrative Analysis and Targeted Therapeutic Validation

    by Wankun Wang, Xiujuan Hong, Xiaoqi Wang, Ganpei Jiao, Hongjie Cai, Junxiang Zhao, Zhibing Wu, Jun Chen

    Biochemical recurrence (BCR) after radical prostatectomy (RP) remains a major clinical challenge. Although metabolic reprogramming drives prostate cancer (PCa) progression, its predictive value for BCR and its interplay with the tumor immune microenvironment (TIME) remain incompletely understood. By integrating weighted gene co-expression network analysis (WGCNA) with machine learning, we identified four metabolic-related hub genes (GDPD1, PLA2G7, PTGDS, and SRD5A2) and developed an XGBoost-Cox model that accurately stratified BCR risk (training 5-year AUC: 0.858; validation 5-year AUC: 0.745). SHAP analysis enhanced the model’s interpretability, while immunohistochemistry (IHC) validated differential protein expression of these targets across 32 clinical specimens. Furthermore, immune profiling demonstrated that these genes are closely linked to M2 macrophage-mediated immunosuppression and altered T-cell infiltration. To translate these biomarkers into therapeutic targets, we employed in silico screening, molecular docking, and molecular dynamics simulations, identifying (-)-epigallocatechin gallate (EGCG) as a promising multi-target candidate. Subsequent in vitro assays confirmed that EGCG binds stably to GDPD1, PTGDS, and SRD5A2, effectively suppressing malignant PCa phenotypes and prostate-specific antigen (PSA) secretion. In summary, we established a robust and interpretable model for predicting BCR after RP, and our in vitro validation suggests that EGCG holds promise as a therapeutic agent to delay PCa progression.


  • Open Access

    Patient-Derived Organoids as a Platform to Decipher and Overcome Radioresistance: From the Tumor Microenvironment to Radiosensitizer Discovery

    by Dashan Yin, Xiujuan Hong, Xiaoqi Wang, Wenjia Ding, Chenli Wang, Jin Qian, Yi Zhou, Chuan Sun, Zhibing Wu

    Patient-derived organoids (PDOs) preserve patient genotypes and 3D architecture, offering a useful platform to investigate mechanisms of radioresistance and test radiosensitizers. We outline an end-to-end workflow—model establishment, multi-omics profiling, pharmacologic screening, and in vivo confirmation—and spotlight immune-competent, vascularized, and organ-on-chip formats. PDOs reveal actionable mechanisms across DNA damage response, hypoxia–metabolic and immune remodeling, and radiation-induced senescence, enabling rational radiosensitizer selection. Paired tumor–normal organoids concurrently gauge efficacy and normal tissue toxicity, refining the therapeutic index. Remaining gaps (incomplete microenvironment, fractionation modeling, and standardization) are being addressed via reporting standards and co-clinical studies, positioning PDOs to support precision radiotherapy.